Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company LigoCyte has entered into a partnership with Biogen to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases including potential respiratory, gastrointestinal, and autoimmune indications.
Subscribe to our email newsletter
Under the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates.
The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.
CD103 is the unique alphaE-beta7 integrin that has been implicated in the activation, homing and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.
Under terms of the agreement, LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for co-development, co-promotion, and sharing of profits resulting from commercialized products.
Donald Beeman, CEO and chairman of the board for LigoCyte, said: “We are very pleased to be entering into this collaboration with Biogen Idec for the development of our lead anti-inflammatory therapy. This strategic alliance confirms the value of LigoCyte’s immunology expertise.”